In one aspect, the disclosure provides cross-linked materials that include multivalent lectins with at least two binding sites for glucose, wherein the lectins include at least one covalently linked affinity ligand which is capable of competing with glucose for binding with at least one of said binding sites; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with glucose for binding with the lectins at said binding sites and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between lectins and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of glucose. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label.

Lectin compositions and methods for reducing tumor cell growth and preventing or treating cancer are provided.

Lectin compositions and methods for reducing tumor cell growth and preventing or treating cancer are provided.

Disclosed herein is the nucleotide sequence of the Chromobacterium subtsugae genome. Also provided are the nucleotide sequences of open reading frames in the C subtsugae genome (i.e., C. subtsugae genes). In addition, the amino acid sequences of proteins encoded by the C. subtsugae genome are provided. Nucleic acids, vectors and polypeptides comprising the aforementioned sequences are also provided. Homologues, functional fragments and conservative variants of the aforementioned sequences are also provided. Compositions having pesticidal, bioremedial and plant growth-promoting activities comprising C. subtsugae genes and proteins, and methods for the use of these compositions, are also provided.

Disclosed herein is the nucleotide sequence of the Chromobacterium subtsugae genome. Also provided are the nucleotide sequences of open reading frames in the C subtsugae genome (i.e., C. subtsugae genes). In addition, the amino acid sequences of proteins encoded by the C. subtsugae genome are provided. Nucleic acids, vectors and polypeptides comprising the aforementioned sequences are also provided. Homologues, functional fragments and conservative variants of the aforementioned sequences are also provided. Compositions having pesticidal, bioremedial and plant growth-promoting activities comprising C. subtsugae genes and proteins, and methods for the use of these compositions, are also provided.

The present invention relates to antiviral lectin and uses thereof. Particularly, the present invention relates to a complex-type (CX-type) and/or hybrid-type (HY-type) glycan binding lectin for use in treating or preventing influenza virus infection. The present invention also provides a method for treating or preventing influenza virus infection by administrating to a subject in need said lectin or a composition comprising the same.

Methods of increasing the biological activity of toxins. Methods of increasing the biological activity of pesticide toxins through the incorporation of pro-regions into nucleic acid constructs for the production of said toxins.

Methods of increasing the biological activity of toxins. Methods of increasing the biological activity of pesticide toxins through the incorporation of pro-regions into nucleic acid constructs for the production of said toxins.

Methods and kits are provided for producing Griffithsin. The methods include providing a genetically modified microorganism comprising a gene encoding Griffithsin protein operably linked to an inducible promotor and growing the genetically modified microorganism under conditions that induce the promotor and cause expression of griffithisin. The Griffithsin is purified by releasing Griffithsin from the microorganism by cellular disruption, performing a precipitation step to remove contaminating protein and nucleic acids, and performing an anion exchange chromatography step.

Provided are a simple and convenient method for preparing universal immune cells and the use thereof. The method comprises placing allogeneic immune cells and specific cell mitogens, cytokines, and immunologic adjuvants in a liquid cell culture medium to be co-cultured in a culture container, so as to obtain a universal immune cell culture with a high immunocompetence. Many clinical long-term practical applications have proven that the universal immune cells are safe and reliable, durable and effective, and have no rejection reaction. Therefore, the universal immune cells can be used as maternal cells of other types of universal immune cell preparations, such as CAR-T and TCR-T, and can be used in fields including adoptive cellular immunotherapy, etc.